Results 51 to 60 of about 4,918 (159)

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

A Multicentre, Prospective, Non‐Interventional Single‐Arm Study Investigating the Impact of Once‐Daily Oral Semaglutide in a Real‐World Adult Population With Type 2 Diabetes in Mexico

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
Initiation of oral semaglutide in patients with T2D in routine clinical practice in Mexico significantly reduces HbA1c and weight and improves satisfaction with treatment. ABSTRACT Background To investigate the oral semaglutide use among Mexican adults with type 2 diabetes.
Guillermo González‐Gálvez, Juan C. Garnica‐Cuellar, Miguel Ángel Colín‐García, Aldo Ferreira‐Hermosillo, Silvia A. Jiménez‐Ramos, Aleida Y. Contreras‐Sandoval, Patricia Cruz‐Puente, Manuel Duarte‐Vega   +7 more
wiley   +1 more source

Patient preference and tolerability of a DPP-4 inhibitor a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study

Therapeutic Advances in Endocrinology and Metabolism, 2015
Objective: The present study aimed to assess the patient preference and tolerability of oral dipeptidyl peptidase-4 inhibitor (vildagliptin) versus injectable glucagon-like peptide-1 analog (liraglutide) in patients with type 2 diabetes mellitus ...
Jörg Lüdemann, Eva D. Dütting, Markus Dworak   +2 more
doaj   +1 more source

Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Aim Adverse events (AEs) detected in tweets and in the FDA Adverse Event Reporting System (FAERS) provide valuable insights into patient experiences with oral hypoglycemic agents including sodium‐glucose transporter 2 (SGLT2) and dipeptidyl peptidase‐4 (DPP4) inhibitors. This study compared the side effects identified from tweets with those in
Se‐Hoon Oh, Dong‐Young Park, Yun‐Kyoung Song   +2 more
wiley   +1 more source

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

Vascular Health and Risk Management, 2008
Chantal Mathieu, Evy DegrandeDepartment of Endocrinology, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose.
Chantal Mathieu, Evy Degrande
doaj  

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Vascular Health and Risk Management, 2012
Sylvie Dejager,1 Anja Schweizer,2 James E Foley31Novartis Pharma SAS, Rueil Malmaison, France; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAbstract: The efficacy and safety of the dipeptidyl ...
Dejager S, Schweizer A, Foley JE
doaj  

Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review

International Journal of Diabetes and Technology
Type 2 diabetes mellitus (T2DM) is a complex disease with multiple pathophysiological defects and generally requires a combination of antidiabetic agents to achieve glycemic targets. In this context, a fixed-dose combination (FDC) of dipeptidyl peptidase-
Subhajyoti Ghosh, Mainak Mukhopadhyay, Mayur Agrawal, Mohammad Shahid, Mahak Lamba, Sudeep Jain, Ashish Prasad, Amit Gupta, Rohan Kesarkar, Sona Warrier, Abhijeet Pednekar   +10 more
doaj   +1 more source

Myocardial-salvaging Effects of a Novel Polyherbal Combination with Dipeptidyl Peptidase-4 Inhibitory Activity

Nigerian Postgraduate Medical Journal
Background: Some of the medicinal plants possess dipeptidyl peptidase-4 (DPP-4) inhibitory properties and could overcome the limitations of synthetic DPP-4 inhibitors.
Devkumar Durgaprasad Tiwari, Ipseeta Ray Mohanty, Ujwala Maheswari, Prithviraj M. Erande, Vandana M Thorat, Aneesa B. Sayed   +5 more
doaj   +1 more source

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

Сахарный диабет, 2013
According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic ...
Gagik Radikovich Galstyan
doaj   +1 more source

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

Diabetes, Metabolic Syndrome and Obesity, 2013
Eleonora Russo, Giuseppe Penno, Stefano Del Prato Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy Background: Dipeptidyl peptidase-
Russo E, Penno G, Del Prato S
doaj